Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 4NETWORK 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 8Recurrent Uterine Corpus Carcinoma 1Recurrence 1Neoplasm Metastasis 1Genetic Diseases, Inborn 1Breast Neoplasm Female 1

Interventions

Vinorelbine 4Dexamethasone 4Filgrastim 3Vincristine 2Peripheral Blood Stem Cell Transplantation 2Granulocyte Colony-Stimulating Factor 2Gemcitabine 2Fenretinide 2Etoposide 2Cytarabine 2Carmustine 2Bortezomib 2zanubrutinib 1relatlimab 1pomalidomide 1pegaspargase 1palbociclib 1liposomal amphotericin B 1ixazomib 1irinotecan sucrosofate 1interferon gamma-1b 1interferon gamma, Cys(-3), Tyr(-2), Cys(-1)- 1imetelstat 1etoposide phosphate 1elotuzumab 1dexamethasone acetate 1dexamethasone 21-phosphate 1carfilzomib 1auricularum 1aldesleukin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Recurrence × Fulvestrant × Clear all
NCT05154487 2026-03-03

A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer

GOG Foundation

Phase 2 Active not recruiting
51 enrolled

Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡